Daclizumab rapidly saturates interleukin-2 receptor-alpha (CD25) on lymph node lymphocytes in children

Transplant Proc. 1999 Feb-Mar;31(1-2):1182-3. doi: 10.1016/s0041-1345(98)01955-1.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II
  • Comparative Study
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / pharmacology*
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antigens, CD / metabolism
  • Child
  • Daclizumab
  • Humans
  • Immunoglobulin G / adverse effects
  • Immunoglobulin G / pharmacology*
  • Immunoglobulin G / therapeutic use*
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / pharmacokinetics
  • Immunosuppressive Agents / therapeutic use*
  • Kidney Transplantation / immunology*
  • Lymph Nodes / immunology*
  • Receptors, Interleukin-2 / metabolism*
  • T-Lymphocyte Subsets / immunology
  • T-Lymphocytes / immunology*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antigens, CD
  • Immunoglobulin G
  • Immunosuppressive Agents
  • Receptors, Interleukin-2
  • Daclizumab